Publication | Closed Access

Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma

First-line TherapyPineal Hormone MelatoninOncologyMedicinePineal GlandImmunologyMetastatic Hepatocellular CarcinomaImmunotherapyPharmacologyTumor MicroenvironmentMelatonin